Background Osteogenesis imperfecta (OI) is a genetic disorder of connective tissue caused
by mutations associated with type I collagen, which results in defective extracellular matrix in …

Background Osteogenesis imperfecta (OI), is a heritable, heterogeneous connective tissue
disorder, characterized by fragile bones. There are conflicting results about genotype …

Osteogenesis imperfecta (OI) is a genetic disease of Type I collagen and collagen-
associated pathways that results in brittle bone behavior characterized by fracture and …

Background Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized
by low bone mass and recurrent fractures. OI patients of autosomal recessive inheritance …

There are no licensed treatments for children with osteogenesis imperfecta. Children
currently receive off-label treatment with bisphosphonates, without any consistent approach …

Osteoporosis in childhood distinguishes itself from adulthood in four important ways: 1)
challenges in distinguishing otherwise healthy children who have experienced fractures due …

Background Chronic pain may affect and interfere in children's everyday life and can be
present in children with Osteogenesis Imperfecta (OI). However, the knowledge is still …

Sclerostin emerges as a novel target for bone anabolic therapy in bone diseases.
Osteogenesis imperfecta (OI) and X-linked hypophosphatemia (XLH) are rare bone …

Abstract Background/Aims: Intravenous bisphosphonate therapy is the first-line treatment in
moderate-to-severe osteogenesis imperfecta (OI), but there are varied treatment protocols …

Introduction: Osteogenesis imperfecta (OI) is a heritable disease characterized by bone
fragility. A wide range of clinical severity and heterogeneity of the molecular defects is …